Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Bi 6727
2. Bi-6727
1. 755038-65-4
2. Bi 6727
3. Volasertib (bi 6727)
4. Bi-6727
5. Bi6727 (volasertib)
6. Volasertib [usan]
7. 6em57086ea
8. Volasertib (usan)
9. Bi6727
10. Bi6727(volasertib)
11. Benzamide, N-(trans-4-(4-(cyclopropylmethyl)-1-piperazinyl)cyclohexyl)-4-(((7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl)amino)-3-methoxy-
12. N-((1s,4s)-4-(4-(cyclopropylmethyl)piperazin-1-yl)cyclohexyl)-4-(((r)-7-ethyl-8-isopropyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-3-methoxybenzamide
13. N-(trans-4-(4-(cyclopropylmethyl)piperazin-1-yl)cyclohexyl)-4-(((r)-7-ethyl-8-isopropyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-3-methoxybenzamide
14. N-{trans-4-[4-(cyclopropylmethyl)piperazin-1-yl]cyclohexyl}-4-{[(7r)-7-ethyl-5-methyl-8-(1-methylethyl)-6-oxo-5,6,7,8-tetrahydropteridin-2-yl]amino}-3-methoxybenzamide
15. Volasertib [usan:inn]
16. Unii-6em57086ea
17. Ibi
18. N-(trans-4-(4-(cyclopropylmethyl)piperazin-1-yl)cyclohexyl)-4-(((7r)-7-ethyl-5-methyl-8-(1-methylethyl)-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-3-methoxybenzamide
19. Bi6727,volasertib
20. Volasertib(bi6727)
21. Volasertib [inn]
22. Bi6727 - Volasertib
23. Volasertib [who-dd]
24. Mls006011195
25. Schembl738946
26. Gtpl7947
27. Schembl2169101
28. Schembl9888052
29. Chembl1233528
30. Chembl4284151
31. Schembl21916558
32. Bcpp000341
33. Dtxsid801099395
34. Dtxsid901025694
35. Bcp02405
36. Ex-a1364
37. Bdbm50402023
38. Mfcd20926414
39. Nsc757149
40. Nsc800965
41. S2235
42. Zinc39716290
43. Akos030257530
44. Zinc100071772
45. Zinc248087828
46. Bcp9000403
47. Ccg-264952
48. Cs-0274
49. Db12062
50. Nsc-757149
51. Nsc-800965
52. Ncgc00263087-01
53. Ncgc00263087-02
54. Ncgc00263087-03
55. Ncgc00263087-12
56. Ncgc00263087-15
57. Ncgc00485964-01
58. Ac-32844
59. As-16996
60. Hy-12137
61. N-[4-[4-(cyclopropylmethyl)piperazin-1-yl]cyclohexyl]-4-[[(7r)-7-ethyl-5-methyl-6-oxo-8-propan-2-yl-7h-pteridin-2-yl]amino]-3-methoxybenzamide
62. Smr004702964
63. Sw218140-2
64. D10182
65. Sr-03000003275
66. Q7939986
67. Sr-03000003275-1
68. 755038-54-1
69. N-((trans)-4-(4-(cyclopropylmethyl)piperazin-1-yl)cyclohexyl)-4-((r)-7-ethyl-8-isopropyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-ylamino)-3-methoxybenzamide
70. N-[cis-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxybenzamide
71. N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxybenzamide
| Molecular Weight | 618.8 g/mol |
|---|---|
| Molecular Formula | C34H50N8O3 |
| XLogP3 | 4.6 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 10 |
| Exact Mass | 618.40058749 g/mol |
| Monoisotopic Mass | 618.40058749 g/mol |
| Topological Polar Surface Area | 106 Ų |
| Heavy Atom Count | 45 |
| Formal Charge | 0 |
| Complexity | 996 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Treatment of acute myeloid leukaemia
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Volasertib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Volasertib, including repackagers and relabelers. The FDA regulates Volasertib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Volasertib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Volasertib supplier is an individual or a company that provides Volasertib active pharmaceutical ingredient (API) or Volasertib finished formulations upon request. The Volasertib suppliers may include Volasertib API manufacturers, exporters, distributors and traders.
Volasertib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Volasertib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Volasertib GMP manufacturer or Volasertib GMP API supplier for your needs.
A Volasertib CoA (Certificate of Analysis) is a formal document that attests to Volasertib's compliance with Volasertib specifications and serves as a tool for batch-level quality control.
Volasertib CoA mostly includes findings from lab analyses of a specific batch. For each Volasertib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Volasertib may be tested according to a variety of international standards, such as European Pharmacopoeia (Volasertib EP), Volasertib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Volasertib USP).
LOOKING FOR A SUPPLIER?
